pulmonary-fibrosis

Documents about pulmonary-fibrosis

• A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)#857799ClinicalTrials.gov
• The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis#858068ClinicalTrials.gov
• Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough#860426ClinicalTrials.gov
• Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.#874144ClinicalTrials.gov
• Linkage Study in Familial Pulmonary Fibrosis#890891ClinicalTrials.gov
• Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis#894838ClinicalTrials.gov
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II#905298ClinicalTrials.gov
• PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort#1008877ClinicalTrials.gov
• An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)#876377ClinicalTrials.gov
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis#810204ClinicalTrials.gov
• A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis#857381ClinicalTrials.gov
• Biomarker signatures for progressive idiopathic pulmonary fibrosis#654950Spiral
• Feasibility & Effect of a Tele-rehabilitation Program in Idiopathic Pulmonary Fibrosis (IPF)#803946ClinicalTrials.gov
• Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)#849136ClinicalTrials.gov
• Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis#916430ClinicalTrials.gov
• Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis#153564HAL (France)
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis#914857ClinicalTrials.gov
• Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough#1007777ClinicalTrials.gov
• The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective#283066ClinicalTrials.gov
• To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)#828048ClinicalTrials.gov
• Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis#870511ClinicalTrials.gov
• Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).#893616ClinicalTrials.gov
• High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib#993661ClinicalTrials.gov
• Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis#1010631ClinicalTrials.gov
• Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis#1030123ClinicalTrials.gov
• Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial#811048ClinicalTrials.gov
• Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis#857929ClinicalTrials.gov
• Senescent Fibroblasts in Aging and Pulmonary Fibrosis#305442ODU Digital Commons
• Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis#811326ClinicalTrials.gov
• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)#852288ClinicalTrials.gov
• Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis#885059ClinicalTrials.gov
• Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomics#890256ClinicalTrials.gov
• PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis#914005ClinicalTrials.gov
• Pulmonary Fibrosis During Severe COVID-19 Pneumonia#1010875ClinicalTrials.gov
• Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis#1045944ClinicalTrials.gov
• Using Health-related Quality of Life (HRQL) in Routine Clinical Care#902962ClinicalTrials.gov
• HOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis#966588ClinicalTrials.gov
• Exercise Hemodynamics in Patients With Pulmonary Fibrosis#850399ClinicalTrials.gov
• Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial#829595ClinicalTrials.gov
• Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis#832227ClinicalTrials.gov
• Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study#836285ClinicalTrials.gov
• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)#889927ClinicalTrials.gov
• Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis#969665ClinicalTrials.gov
• A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough#1047636ClinicalTrials.gov
• Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations#146204ClinicalTrials.gov
• Protocol for the INterstitial lung Disease EXacerbations (INDEX) Study: a retrospective multicentre cohort study.#451388Apollo
• A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis#882508ClinicalTrials.gov
• Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis#350044ClinicalTrials.gov
• Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis#828404ClinicalTrials.gov
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis#872586ClinicalTrials.gov